James Hardie Industries (JHX) – Questions to be asked

James Hardie Industries engages in the manufacture and sale of fibre cement, fibre gypsum, and cement bonded boards in the US, Australia, Europe and New Zealand. The company offers its products under the HardieTM brand, such as Hardie Plank, Hardie Panel, Hardie Trim, Hardie Backer, Hardie Artisan Siding, and HardieTM Architectural Collection brands, as well as the fermacell and AESTUVER brands. The company was founded in 1888 and is headquartered in Dublin, Ireland.

Ord Minnett has reviewed its James Hardie Industries model to reflect the impact on earnings of continued weak residential housing and construction data in its key US market and the imminent issuance of shares to part-fund the acquisition of US-based artificial decking manufacturer AZEK.

We expect a fall of 16% year-on-year (YoY) in first-half FY26 net profit, mainly due to soft volumes, prices and margins in the North American Fibre Cement (NAFC) division. Our estimates for those metrics are all below what the broader market expects, with our net profit number circa 8% short of consensus.

Operating earnings guidance for the existing James Hardie businesses was for a low single-digit percentage increase in FY26, and Ord Minnett’s estimate is 1.7%, albeit this incorporates some market share gains and an improving American macroeconomic environment as the Federal Reserve cuts interest rates. The key question for investors is whether AZEK can maintain the robust 10% growth in operating earnings that the market is expecting in FY26 under the stewardship of James Hardie management, noting that acquired companies typically fall short of growth expectations as new businesses are integrated into the new parent company.

Post our review, we have cut our EPS forecasts by 8.4%, 3.6% and 3.3% for FY26, FY27 and FY28, respectively, to incorporate earlier completion of the AZEK transaction, weak US market conditions, and higher interest expenses. We maintain our Hold recommendation on James Hardie while our target price rises to $41.50 from $40.00 as we roll forward our valuation timeline.

‍